@article{019abb9fa5ba471b9a39a4c6cf6437fb,
title = "Prediction of Stroke Infarct Growth Rates by Baseline Perfusion Imaging",
abstract = "BACKGROUND AND PURPOSE: Computed tomography perfusion imaging allows estimation of tissue status in patients with acute ischemic stroke. We aimed to improve prediction of the final infarct and individual infarct growth rates using a deep learning approach. METHODS: We trained a deep neural network to predict the final infarct volume in patients with acute stroke presenting with large vessel occlusions based on the native computed tomography perfusion images, time to reperfusion and reperfusion status in a derivation cohort (MR CLEAN trial [Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands]). The model was internally validated in a 5-fold cross-validation and externally in an independent dataset (CRISP study [CT Perfusion to Predict Response to Recanalization in Ischemic Stroke Project]). We calculated the mean absolute difference between the predictions of the deep learning model and the final infarct volume versus the mean absolute difference between computed tomography perfusion imaging processing by RAPID software (iSchemaView, Menlo Park, CA) and the final infarct volume. Next, we determined infarct growth rates for every patient. RESULTS: We included 127 patients from the MR CLEAN (derivation) and 101 patients of the CRISP study (validation). The deep learning model improved final infarct volume prediction compared with the RAPID software in both the derivation, mean absolute difference 34.5 versus 52.4 mL, and validation cohort, 41.2 versus 52.4 mL (P<0.01). We obtained individual infarct growth rates enabling the estimation of final infarct volume based on time and grade of reperfusion. CONCLUSIONS: We validated a deep learning-based method which improved final infarct volume estimations compared with classic computed tomography perfusion imaging processing. In addition, the deep learning model predicted individual infarct growth rates which could enable the introduction of tissue clocks during the management of acute stroke.",
keywords = "Deep learning, Infarction, Ischemic stroke, Perfusion imaging, Reperfusion",
author = "Anke Wouters and David Robben and Soren Christensen and Marquering, {Henk A} and Roos, {Yvo B W E M} and {van Oostenbrugge}, {Robert J} and {van Zwam}, {Wim H} and Dippel, {Diederik W J} and Majoie, {Charles B L M} and Schonewille, {Wouter J} and {van der Lugt}, Aad and Maarten Lansberg and Albers, {Gregory W} and Paul Suetens and Robin Lemmens",
note = "Funding Information: The MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) was partly funded by the Dutch Heart Foundation and by unrestricted grants from AngioCare BV, Medtronic/Covidien/EV3, Medac Gmbh/Lamepro, Penumbra Inc, Stryker, and Top Medical/Concentric. Funding Information: The MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) was partly funded by the Dutch Heart Foundation and by unrestricted grants from AngioCare BV, Medtronic/Covidien/EV3, Medac Gmbh/Lamepro, Penumbra Inc, Stryker, and Top Medical/Concentric. Funding Information: Dr Marquering reports co-founder and shareholder of Nico-lab outside the submitted work. Dr Roos reports stock ownership of Nico-Lab outside the submitted work. Dr Majoie reports grants from CVON (Netherlands Cardiovasculair Research Initiative)/Dutch Heart Foundation, grants from European Commission, grants from Dutch Health Evaluation Program, grants from Stryker, and grants from TWIN Foundation (Toegepast Wetenschappelijk Instituut voor Neuromodulatie) outside the submitted work; and is shareholder of Nico-lab. Dr van der Lugt reports grants from Angiocare BV, grants from Covidien/EV3, grants from Medac GmbH/Lamepro, grants from Stryker, grants from Penumbra, and grants from Dutch Heart Foundation during the conduct of the study; grants from stryker, grants from Medtronic, grants from penumbra, grants from cerenovus, and grants from thrombolytic science Inc outside the submitted work. Dr Lansberg reports grants from National Institutes of Health during the conduct of the study. Dr Albers reports equity interest in iSchemaView, owner of RAPID software which is used in this study. Dr Christensen reports equity interest in iSchemaView, owner of RAPID software which is used in this study. Dr Dippel reports grants from Dutch Heart Foundation, grants from AngioCare BV, grants from Covidien/EV3, grants from MEDAC Gmbh/LAMEPRO, grants from Penumbra Inc, grants from Top Medical/Concentric, grants from Stryker, during the conduct of the study. Dr van Zwam reports personal fees from Cerenovus and personal fees from Stryker during the conduct of the study. Dr Robben reports grants from Flanders Innovation and Entrepreneurship (VLAIO [Agency for Innovation and Entrepreneurship]) during the conduct of the study; in addition, Dr Robben has a patent to Patent for automatic arterial input function selection pending. Dr Lemmens is a senior clinical investigator for Fund for Scientific Research-Flanders (FWO: 1841918 N), reports a grant from FWO Flanders (G049620N) and institutional support for consultancy by iSchemaView. The other authors report no conflicts. Publisher Copyright: {\textcopyright} 2021 American Heart Association, Inc.",
year = "2022",
month = feb,
day = "1",
doi = "https://doi.org/10.1161/STROKEAHA.121.034444",
language = "English",
volume = "53",
pages = "569--577",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams & Wilkins",
number = "2",
}